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A collection of perspectives and panel discussion 
We have come far, but selecting organ recipients remains an ethical minefield 
By Denton A. Cooley, MD 
Only 40 years ago, on December 3, 1967, the world 
was electrified by news of the first cardiac transplanta-
tion, performed in Cape Town, South Africa, by the 
renowned Dr. Christiaan Barnard. 
We have progressed considerably since that time, but 
not all issues have been settled. After several attempts 
by Dr. Norman Shumway and by Dr. Adrian Kant-
rowitz in this country, we in Houston performed the 
first successful cardiac transplantation in the United 
States in April 1968. Initially we were impressed with 
the results, and we embarked upon a very active car-
diac transplant program, performing as many as had 
been done in total around the world. But after we had 
done some 15 or 20 cardiac transplants, the discourag-
ing news began to emerge that the patients were not 
surviving long: our longest survived for only 2 years. 
As a result, our group in Houston, like others, 
declared a moratorium on cardiac transplantation. 
The only group that continued throughout this era 
was at Stanford University under Shumway, who had 
some success with immunosuppressive drugs. In the 
early 1980s, a new immunosuppressant, cyclosporine, 
appeared that was used for kidney transplantation, 
which reinvigorated us and others to use this drug 
for cardiac transplantation. Since then, under the 
direction of my colleague, Dr. Bud Frazier, we have 
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perfOlmed more than 1,000 cardiac transplantations 
at the Texas Heart Institute. 
From the beginning, we were called upon to 
identify appropriate donors and suitable recipients. 
Although we rely on certain objective factors, such as 
age, weight, body size, gender, and blood type, many 
other issues must also be considered. Fortunately, 
the modem concept of brain death has now been 
accepted not only by the public and ethicists, but also 
by the legal community; in contrast, at one time it 
was considered homicidal to remove a beating heart. 
I credit Christiaan Barnard with having the courage 
to remove a beating heart from a 26-year-old donor 
who had suffered irreversible brain damage. Many of 
us had wanted to get into the transplant program, but 
we could not identify a donor. 
The following case illustrates some of the other 
ethical complexities that we continue to struggle 
with today. 
• CASE STUDY: A 17-YEAR-OLDWITH HEART FAILURE 
AND A DESTRUCTIVE LIFESTYLE 
Several years ago, a 17 -year-old Latin American boy 
came to our clinic in heart failure. He was very dis-
arming, but when we looked into his background we 
found that he had dropped out of high school after 1 
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year and was living with a girlfriend who was 2 months 
pregnant by him and already had a 2-year-old child. 
The patient's cardiomyopathy was related to cocaine 
and alcohol abuse. Nevertheless, his stepfather was 
eligible for Texas Medicaid, and he was accepted for 
cardiac transplantation. 
After the transplantation, he abided by the 
immunosuppressive dmg regimen while he was under 
our care. Then he moved to Fort Wayne, Indiana, 
where Indiana Medicaid would not honor his Texas 
Medicaid coverage. So our hospital had to send him 
his immunosuppressive dmgs, which he used rather 
sporadically. 
While in Indiana, he was incarcerated for assault 
and battery on his girlfriend. He began to have heart 
failure but did not qualify to have the biopsies required 
for proper study of rejection of his heart. He returned 
to our clinic and was scheduled for catheterization 
the next day when he went into acute cardiac failure. 
He had emergency late-night implantation of a per-
cutaneous ventricular assist device, which required 
catheterizing the left atrium by perforating the inter-
atrial septum, taking the oxygenated blood out of the 
left atrium, and pumping it back into the aorta with 
a centrifugal pump. His heart began to recover, and 
the device was removed after 72 hours. 
At this point he needed another transplantation. 
Our medical review board considered his eligibil-
ity and turned him down, citing that others on our 
waiting list were more deserving of a transplant and 
that retransplantation has a poorer success rate than 
initial transplantation. 
• EACH CASE POSES PROBLEMS, 
BUT A RECORD OF SUCCESS EMERGES 
Although this patient could be viewed as a sort of 
sociopath, he nevertheless is a young man who is 
incapacitated and in need of heroic measures. His case 
illustrates the kind of nonmedical problems that face 
those of us who are actively involved in cardiac trans-
plantation. It can be very difficult to find solutions to 
the myriad social, economic, legal, and ethical issues. 
We perform about 50 transplants a year in our insti-
tution, and every one of them has some issue. Never-
theless, we just honored 25 patients who have survived 
more than 20 years with cardiac transplantation. 
Despite the odds, the transplant field has progressed rapidly 
By John J. Fung, MD, PhD 
Dr. Pauline Chen's clinical vignette [see previous 
article in this supplement] unfortunately still typifies 
small bowel transplantation. One would not expect 
to hear that kind of story today for a kidney or liver 
transplant, but in the early 19705 it was typical. 
We perform transplantations because we know 
that the alternative is prolonged morbidity and 
death. Knowing that we can provide a touch of hope 
is why we move forward in this field. 
The technology of transplantation has developed 
through aggressive scientific develop-
• 'WHY WOULD ANY YOUNG 
PHYSICIAN WANT TO GET 
INVOLVED IN THIS?' 
Dr. Cooley's comments about the 
moratorium on cardiac transplanta-
tion brought back memories for me, 
particularly from when I was studying 
liver transplantation in the 1970s. 
There was almost uniform mortality in 
transplants performed in the late 1960s 
If we had proceeded 
in a very stepwise 
manner, we probably 
w()uld not be even a 
tenth as far along in 
the transplant field 
ments in the laboratory. It is fascinat-
ing that all this has developed in only 
50 years. If we had proceeded in a very 
stepwise manner, we probably would 
not be even a tenth as far along in the 
field as we are now. 
Heart, lung, liver, and kidney trans-
plantation are now all pretty routine. 
Intestinal transplantation is in the 
developing phase. The Cleveland 
as we are now. 
and early '70s. One wonders why any 
young physician would have wanted to 
get involved in transplantation at that time. I was a 
fellow training with Dr. Thomas Starzl at the Uni-
versity of Pittsburgh and remember him saying, "Just 
make it work, then let everybody else figure out why." 
I think that typifies the surgical mentality. 
---:Dr. John Fung 
Clinic is currently involved in facial 
transplantation, which has some dif-
ferent ethical issues related to identity. 
Everything in transplantation relates to ethics, 
from issues about using marginal donor grafts or 
using beating-heart donors when someone has not 
been declared brain dead, to issues in patient selec-
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tion, which often depends on social, economic (ie, 
insurance coverage), and psychosocial factors such as 
substance abuse and nonadherence issues. 
• ETHICAL INSIGHTS FROM TRANSPLANTS 
IN HIV-POSITIVE PATIENTS 
An ethical area of particular interest to me that the 
Cleveland Clinic has also been involved with is 
transplanting patients who are HIV-positive. This has 
always been an enigma: why would we want to trans-
plant an HIV-positive patient? Before the advent of 
antiviral therapies for HIV in the mid-1990s, mor-
tality rates were very high, with patients suffering 
miserable deaths from Kaposi sarcoma, the ]C virus 
leukoencephalopathies, and other debilitating oppor-
tunistic infections. 
When I first arrived at the University of Pittsburgh 
as a fellow, Dr. Starzl was telling us about this mys-
tery virus disease; when they retrospecti.vely analyzed 
specimens from organ recipients and donors, they 
realized that HIV was being transmitted to patients 
from donors as well as from blood transfusions. The 
exposure to health care providers was also substantial: 
an average of 20 to 30 units of blood was used for a 
liver transplant. 
Patients who were HIV-positive were excluded from 
transplants even through the mid-1990s. I remember 
evaluating standard listing criteria for transplant 
recipients at a conference and hearing transplant sur-
geons say that HIV is an absolute contraindication to 
transplant. I said, "Wait a minute, this is 1997; you 
cannot say that. Given that attitude, patients with 
HIV will never be transplanted." The New England 
Journal of Medicine had just published a major paper 
about the extent of survival in patients being treated 
with highly active antiretroviral therapy. 
So we then started a prospective study of transplan-
tation in HIV-positive patients, and long-term follow-
up has shown that these patients can do very well. 
Interestingly, transplantation offers a new approach 
to treating HIV-positive patients, in terms of immune 
reconstitution and the ability of immunosuppressive 
agents to restore immune competency by preventing 
the T-cell apoptosis initiated by HIV infection. 
A continued need for evidence-based guidance 
By James B. Young, MD 
Speaking as the lone internist on this panel, and 
also as a clinical trialist and evidence-based clinical 
practitioner, the greatest ethical challenge I see for 
transplantation is how to move the field forward in 
terms of garnering evidence that can 
fewer heart transplants are being done in the 
United States in this decade than in the 1990s,2 
in large part because other effective interventions 
for heart failure have been developed. However, 
the number of heart transplants is in 
help us treat patients and keep them 
alive. Nobody will deny that heart 
transplantation is life-saving therapy: 
my patients with end-stage ischemic 
cardi.omyopathy can be dramatically 
transformed by a heart transplant after 
being near death. The questions now 
are how best to gain the data to guide 
the next round of innovations in trans-
plant medicine and how to know when 
Heart transplant is a bit 
of a boutique science, 
so questions arise 
about how to evaluate it 
with the rigor of 
regulatory authority. 
fact on the rise again. 2 Second, sur-
vival rates in heart transplant have 
improved substantially in recent 
years compared with earlier eras, as 
documented by registry data from 
the International Society for Heart 
and Lung Transplantation. l 
-Dr. James Young Among other things, we have 
learned how to improve the opera-
the time is right to attempt those innovations. 
• A HISTORICAL GLANCE AT HEART TRANSPLANTATION 
Dr. Sharon Hunt, who was one of the first heart 
transplant cardiologists and worked with Dr. Nor-
man Shumway, almost singlehandedly moved 
the field of cardiac transplantation forward. She 
recently chronicled its history,l and this sort of 
historical review yields a couple of insights. First, 
tion, better choose and preserve 
hearts, and better match hearts to recipients. We 
now can use hearts from older donors and allow 
older patients to undergo transplantation. One of 
the keys to the better survival rates is a dramatic 
change in the use of medications. Cyclosporine 
allowed for successful heart transplantation in the 
1980s, and we have since seen the advent of agents 
such as tacrolimus, rapamycin, and mycophenolate 
mofetil. We rely less on the early immunosuppres-
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FIGURE 1. Flow chart of 
evidence-based medical 
practice. The drive for new 
knowledge is circuitous, 
beginning with clinical 
experience and observation 
and ultimately feeding back 
into clinical practice and 
further research prompted 
by new experience. • Patient responses • Public health issues • Continuous quality improvement initiatives 
sants, such as prednisone and azathioprine. 
Despite these successes from a survival standpoint, 
problems still need to be addressed. For instance, 
at 5 years, virtually every patient following a heart 
transplant develops hypertension and dyslipidemia, 1 
in 3 has renal dysfunction (some requiring dialysis or 
transplant), 1 in 3 has diabetes, and some develop a 
strange allograft arterioparhy.l 
• THE CHALLENGE OF EVALUATING 
A BOUTIQUE SCIENCE 
Heart transplantation is a bit of a boutique science. 
Although relatively few heart transplants are per-
formed compared with liver or kidney transplants, 
heart transplantation is a dramatic operation limited 
by many ethical challenges surrounding organ donor 
supply and utilization. 
As for any boutique science, questions arise 
about how to evaluate it with the rigor of regulatory 
authority-from both the Food and Drug Admin-
istration (FDA) perspective and the institutional 
review board ORB) perspective-without large clini-
cal trials. Suppose that Dr. Cooley wants to make a 
minor modification in his immunosuppressive proto-
col because of an observation of a high incidence of 
renal failure at the 5-year point; does that ethically 
demand a large randomized clinical trial? 
How can we design clinical trials to help deter-
mine which direction to take in immunosuppression 
intensification or utilization protocols? Other chal-
lenges include evaluating outcomes (such as coro-
nary artery vasculopathy) from databases, and then 
figuring out good and bad practices. For example, 
databases show us that a donor history of diabetes 
increases the recipient's long-term risk of devel-
oping coronary artery vasculopathy.' Receiving a 
heart from a male donor also increases risk.3 Better 
understanding the panoply of adverse events and 
what leads to better outcomes will give us a sense of 
how to proceed and can drive the design of clinical 
trials. 
• OTHER ETHICAL CHALLENGES 
From an ethical standpoint, how do we change prac-
tice? We have data on outcomes at 5, 10, and even 
20 years. The half-life of a heart transplanted today 
is 12.5 years, whereas it llsed to be about 7 years.3 
Although it is clear that we have made progress, it is 
a challenge to determine exactly how to make subtle 
changes in practice, such as addressing polypharmacy 
post-transplant. 
Developing schemes that enable major innova-
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tion, particularly through coordination among 
medical and surgical teams, is another challenge. 
For example, we are working with preservation 
techniques that use a beating heart for transplanta-
tion. From solid evidence based on animal models, 
we believe this preparation can allow preservation 
of a heart for up to 12 hours. To some, that may 
beg a number of questions: Why do we need to do a 
clinical trial in humans? Why does the FDA need to 
regulate us? Why do we even need to answer to an 
IRB? Why not just make the change to alleviate the 
problem of donor organ supply? 
My perspective is that I believe in evidence-based 
medicine and in clinical trials. I believe we should 
try to ethically move the field forward by taking a 
clinical experience or an observation and moving it 
through all the necessary elements of evaluation and 
treatment strategy development (Figure 1) to drive 
knowledge. I believe this applies to post-heart trans-
plant patients as much as it does to patients with 
conditions such as heart failure or ischemic heart 
disease. 
What does-and does not-spur innovation? 
By Thomas E. Starzl. MD, PhD 
• LESSONS FROM THE CODMAN ANALYSIS 
OF FAILURES 
Dr. Ernest Codman was a Harvard Medical School 
professor in the early 20th century who tried to intro-
duce a system of analyzing failures at Massachusetts 
General Hospital and other Harvard-affiliated hospi-
tals. As a result, he was metaphorically ridden out of 
town on a rail. 
Codman recommended that complications and 
failures be classified as one of the following: 
• An error in diagnosis 
• An error in judgment 
• An error in technique (if a surgical or a medical 
problem) 
• An error in management. 
Only one escape hatch existed that did not indict 
the surgical or medical team as culpable: the disease. 
At the time, nothing could be done for many dis-
eases, including cancer, heart disease, renal failure, 
and bowel insufficiency. 
This is a type of analysis that can be brought to 
a mortality and morbidity conference and will not 
accept a lot of alibis; it forces the group to always 
look at what could have been done to prevent a com-
plication or death. Some practitioners always want to 
blame some factor other than themselves: sometimes 
the patient, by being deemed noncompliant, is even 
held responsible for his or her own complication or 
death. 
I think the Codman analysis of failures is a good 
starting point for discussing innovations, especially 
since true breakthroughs come in those cases where 
the failure falls into the category of being caused by 
the disease itself, not by a medical or surgical error. 
And that is surely where transplantation falls. 
• PROGRESS DOES NOT ALWAYS REQUIRE 
FULL UNDERSTANDING 
Transplantation was first successfully performed in 
the context of breaking through the donor-recipient 
genetic barrier on January 6, 1959, when Joseph 
Murray and his team at the the Brigham Hospital 
performed a kidney transplant using the patient's 
fraternal twin as a donor. This event was reproduced 
in Paris by Jean Hamburger and his team on June 
14, 1959, and then on three or four other occasions 
in the next several years in patients who received 
sublethal total body irradiation. This was at a time 
when no pharmacological immunosuppression was 
available, so no follow-up treatment was offered. 
Astoundingly, the first case-the fraternal twin-
lived for more than 20 years, and the French case for 
25 years, without ever being treated with immuno-
suppression. They were inexplicably tolerant. When 
immunosuppressive drugs were developed and sur-
vival rates improved, the questions around these early 
cases were never answered: Why did those transplan-
tations work? What were the mechanisms of engraft-
ment? What was the relationship of engraftment to 
tolerance? Without answering those questions, there 
was no way to make other big leaps in improvement 
of what was already proved in principle-that is, the 
feasibility of actually doing this kind of treatment. 
Improvements in patient and graft survival were 
dependent almost entirely on better drugs. 
• RANDOMIZED TRIALS HAVE A DUBIOUS 
RECORD IN TRANSPLANTATION 
I know this will offend just about everyone here, but 
I have no confidence in evidence-based therapy if 
we are talking about randomized trials. None of the 
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great advances in transplantation has had anything 
to do with randomized trials. In my opinion, ran-
domized trials in transplantation have done nothing 
but confuse the issue and have very nearly made it 
impossible for the better immunosuppressants to be 
brought on board. Cyclosporine offered a tremendous 
step forward, but the randomized trials, carried out 
mostly in Europe, did not reveal much difference in 
outcome from treatment with azathioprine, at least as 
assessed by patient and graft survival. The same thing 
occurred when tacrolimus emerged; randomized mul-
ticenter trials actually delayed the widespread use of 
this superior drug for at least half a dozen years. 
• IN THE BIG PICTURE, 
MONEY IS HOBBLING INNOVATION 
Earlier it was debated whether money drives every-
thing. I do not believe that money 
.. 
dying and the central question was, "How can I treat 
this patient?" They did laboratory research on their 
own to produce evidence that a new innovative idea 
could work. I believe that if you have experiments 
that show that you can keep a heart beating on a 
preservation device for 12 hours, and you can put it 
in a dog and it works well, that is the evidence you 
need to proceed. How are you going to do a random-
ized trial-hang on to an organ and let it beat for 12 
hours just so it conforms with some protocol? That is 
nonsense. 
There was a period when clinical journals-Sur-
gery of Gynecology and Obstetrics, Annals of Surgery, 
Annals of Internal Medicine, New England Journal 
of Medicine-published front-running discoveries. 
That ended about 25 years ago when it became more 
important to learn about details. The journals then 
became superfluous, and for another 
drives everything in medicine in 
Europe, and it certainly has little to do 
with driving improvements in Asia. 
But money does drive everything in 
the United States, although the real 
question is whether it has to be that 
way. 
Randomized trials reason as well: money drove the wheel 
more and more. Hospital and program 
administrators expected the publica-
tions to be advertisements, and the 
minute that articles started promot-
ing something rather than report-
ing facts, they lost value. Today the 
impact factors of the surgical journals 
are at about 2 or 3, meaning that their 
articles are cited infrequently and 
have have little real influence on the 
practice of medicine. 
I believe that innovation is some-
how built within our genome. Many 
of the great advances in transplanta-
tion, the elucidation of principles, 
and the relatively recent discovery of 
the mechanisms of alloengraftment 
in transplantation 
have done nothing 
but confuse the issue 
and have very nearly 
made it impossible 
for the better 
immunosuppressants 
to be brought on board. 
-Dr. Thomas Starzl 
were achieved without grant support. 
The researchers involved could not have asked for 
National Institutes of Health funding because their 
ideas were so far out of the box that they probably 
would have been rejected or stolen. 
I wonder to what extent the vast amount of money 
available for research is actually a disincentive for 
genuine advancements. Part of the problem is that 
the power of allocation is put in the hands of anony-
mous peer-review committees. That system generates 
droves of people to pursue money allocated to a cer-
tain area to learn more and more about less and less, 
in the vague hope that acquiring enough details will 
result in a realistic concept. Sometimes the picture 
simply becomes more confused. 
Another problem is that we have produced far 
more scientists than jobs, so that funding becomes the 
first priority because it is the only means of employ-
ment. In earlier days, what drove people more often 
was that they were confronted with a child who was 
How did we reach this point where 
money drives everything? I think the 
page was turned in the very early 1990s, and it had to 
do with how medical practice is governed, especially 
in academic hospitals. Half of the health care in this 
country is now provided by hospitals that are associ-
ated with medical schools. Those hospitals and basic 
research laboratories contain our young people and 
are where they will assimilate their ideals. If that 
climate is not right, then we are raising the wrong 
kind of doctors. 
Earlier researchers looked at a problem and 
thought, "Here's a question that has to do with this 
patient before my eyes, and I must find some way 
to solve it. Let's go to the laboratory." Today there 
is a real danger that they are thinking, "I need to 
advance my career, so let's see how I can get some 
money. A little research will be a stepping stone to 
my professional development." Our discussion of 
medical and surgical ethics today should take place 
within this framework. 
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Panel discussion 
Moderated by Mark Siegler, MD 
• WERE FINANCES A DRIVER OF EARLY 
TRANSPLANT INNOVATION? 
Dr. Mark Siegler: It is clear that there are more 
and less ethical ways to introduce innovations. I am 
reminded of an article in JAMA by Francis Moore in 
the late 1980s in which he warned that one of the 
things to look at for any new innovation was the ethi-
cal climate of the institution.4 He cautioned us to be 
very aware of the driving force behind an innovation. 
Is it to improve patient care? To save lives that oth-
erwise would be lost? Or is it primarily for the self-
aggrandizement of an investigator or the financial 
goals of an institution? 
I also remember the chapter in Dr. 
to represent and protect them. I have also always felt 
that those of us in these positions have an obligation 
to become innovators. Surgeons who merely see how 
many appendectomies or cholecystectomies they can 
perform are being very derelict of their responsibility 
to the institution. 
• MEASURING SUCCESS IN HEART TRANSPLANTATION 
Dr. Siegler: Dr. Cooley, what is the current success 
rate for heart transplants? 
Dr. Cooley: Nationwide, around 90% of recipients 
survive 12 months. Of those, maybe half are still alive 
5 years later. Of course, we do not know 
Starzl's book The Puzzle P eople5 about the 
anguish involved in introducing liver 
transplantation. It seems that financial 
considerations were not the driver of 
major steps forward in introducing liver 
transplantation, in Dr. Starzl's case, or 
heart transplantation, in Dr. Cooley's 
case. Would you comment? 
Those of us privileged to 
spend our entire career 
in academic settings, 
with institutions to 
represent and protect us. 
have an obligation to 
become innovators. 
what the future will hold. It is interest-
ing that the first sign of rejection seems 
to be coronary occlusive disease. It is 
a different type of coronary occlusive 
disease than is seen in atherosclerosis: 
it is diffuse, involving the entire extent 
of the coronary circulation, and is not 
really amenable to coronary bypass or 
other interventional procedures. 
Dr. Thomas Starzl: Actually, not only 
were we not driven by economic gain, 
-Dr. Denton Cooley 
we expected financial penalty for focus-
ing on transplantation. If ever there was a field that 
developed against the grain, that was costly to people 
who worked in it, whose engagement meant that for 
most of their career they would work for substandard 
income compared with their peers--even those peers 
in academic medicine, let alone those in private 
practice-it would be transplantation. 
It was not until 1973, when the end-stage renal 
disease (ESRD) program began under Medicare, that 
cash for transplantation started to become available. 
The real cash streams did not start until the middle 
to late 1980s when nonrenal organs became the cash 
cows. To be fair, no new technology can be assimi-
lated into the health care system unless it at least 
pays for itself. But you can go beyond that and create 
baronial kingdoms, and I think that is where you can 
go wrong. 
Dr. Denton Cooley: I would add that those of us 
privileged to spend our entire career in academic set-
tings have an opportunity that others may not have. 
A lot of brilliant people in private practice are capable 
of doing many things but do not have an institution 
Dr. Siegler: We are now at about the 
40th anniversary of the first human 
heart transplants, an extraordinary and historic inno-
vation. Dr. Cooley, do you think the timing was right 
in 1968 when you did the first heart transplant in the 
United States? In retrospect, would you have done 
the first transplant sooner or maybe even a couple of 
years later? 
Dr. Cooley: You can argue it both ways. Should we 
have waited for further developments? At the time, 
heart transplantation seemed to work fairly well in 
animals, but we never really know until it reaches the 
clinical level. It was probably as opportune a time as 
any. We knew something about organ rejection at the 
time, and we had immunosuppressive drugs, although 
they were not as effective as they are today. The news 
electrified the world. I think we were pretty well pre-
pared for this spectacular event. 
Dr. Siegler: When would have been the optimal time 
to do a clinical trial in order to achieve evidence-
based medicine in heart transplantation? Would it 
have been during the big breakthroughs of Shumway, 
Barnard, and Cooley, or now, when we have the gen-
eral strategy and can find out how we can do better? 
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Dr. J ames Young: I would not have done a random-
ized trial at that time. The patients who were getting 
transplanted then were nearly dead; all other man-
agement was futile. In 1970, Life magazine listed the 
102 heart transplants that had been done around the 
world up to that point, and maybe only 2 or 3 of the 
patients were still alive. That prompted the morato-
rium that Dr. Cooley referred to. 
As ethical clinicians, we are supposed to do our 
best to make our patients feel better and make them 
live longer. Sometimes you have to do something rad-
ical. On that basis, one can argue that we should not 
transplant "the walking wounded," that instead we 
should save organs for patients who are truly terminal 
without some sort of ventricular replacement therapy. 
But today we are getting away from transplanting only 
dying patients, so we need randomized 
tat ion-the donor, the reCipient, and the patient 
still on the waiting list because the organ went to the 
recipient instead-also motivates the team with a 
sense of obligation to the two unseen patients. 
If there is a lesson about the ethics of letting go, I 
think it is that we often fail to talk about these issues 
among ourselves. Perhaps if we had discussed end-
of-life care or palliative care in Max's case, we might 
have had more insight into the pressures we felt in 
considering the lives of three separate people. And 
those discussions might have-or might not have-
changed the situation. 
Dr. Starzl: I agree completely with the preceding 
comments. All kinds of motivations might cause a 
surgeon to cling too long-the ones that were men-
tioned as well as some ignoble ones, 
trials to find out how we are doing in 
transplanting outpatients. That is the 
setting in which trials are now needed. 
• THE ETHICS OF 'LETTING GO' 
Question from audience: Dr. Chen's 
story [see previous article] raised the 
issue of the ethics of "letting go" of 
one's patient. I wonder if in transplan-
tation, especially when innovative pro-
cedures are involved, a commitment to 
the procedure itself might sometimes 
conflict with the need to let go of the 
patient. 
For my vintage of 
transplant surgeons, 
death and failure are 
rarities and are truly a 
sort of enemy, whereas 
prior generations of 
surgeons are wiser and 
perhaps have a better 
sense of when it is time 
to stop intervening. 
such as vanity, in terms of looking at 
one's survival numbers. 
I would also like to take a much 
larger view. Some years ago in Colo-
rado, the governor at the time, Rich-
ard Lamm, thought that intensive care 
units (ICUs) were harmful-that they 
were economically draining, did not 
serve society, and prolonged suffer-
ing. My position, which was really the 
opposite, was that maybe he was right 
in his philosophy but transplanta-
tion had, in a sense, changed all that. 
-Dr. Pauline Chen 
Dr. John Fung: In the United States, we measure 
efficacy and benefits in different ways than people 
do in other parts of the world. Here, for a child with 
a biliary atresia-the most common reason for liver 
transplantation-we expend hundreds of thousands 
of dollars for a liver transplant, which is usually able 
to save the child's life. But in China, a severely ill 
child is viewed as a medical and economic liability 
and will be allowed to die so the family can have 
another child. 
It is also not only the ethics of letting go. We all 
deal with letting go, not just in transplant medicine. 
It is also the ethics of actually getting a patient into 
the system. In the case of transplanting a newborn, 
as in Dr. Chen's narrative, should they even have 
embarked on that? 
Dr. Pauline Chen: For me, the story illustrates the 
remarkable connection and profound attachment 
between a surgeon and his or her patient. The fact 
that three patients are really involved in transplan-
Transplantation took desperate people 
who were in the ICU, with no chance 
of coming out, and dramatically returned them to 
wonderful health. 
As procedures get better, this scenario happens 
more and more often. I agree that there is a time 
when you realize that no intervention will work and 
you should stop treatment. That is a bitter pill. But it 
is very hard to define when that moment occurs. 
Dr. Chen: There also may be somewhat of a genera-
tional difference in approach. 
Most surgeons will fully acknowledge that they 
stand on the shoulders of giants, and that holds par-
ticularly true in a field like transplantation. When 
I was training in liver transplantation, for example, 
80% to 90% of the patients could fully expect to sur-
vive 5 years. For my vintage of surgeons, then, death 
and failure were rarities and they were truly a sort of 
enemy, whereas surgeons like Dr. Starzl and Dr. Cooley 
have seen so much more and are far more used to all 
the variations of outcomes. Because of that breadth of 
experience that you have, I think you are wiser than 
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my generation of surgeons, for whom death often has 
to be ablated at all costs. I think it follows, then, that 
you would also have a better sense of when to stop. 
Dr. Starzl: There is a generational change-there is 
no doubt about it. 
III IS TRANSPLANT ETHICAL WHEN A LIFE 
IS NOT AT STAKE? 
of immunosuppression, this type of transplantation 
can become worthwhile. Putting a new hand or face 
on someone is astounding: it changes the morphology 
of the brain, which can be observed with functional 
magnetic resonance imaging. It changes the soul, if 
that is what you want to think of when talking about 
the brain. I think it will be very important. 
Question from audience: What are the 
ethical implications of non-lifesaving 
transplants, specifically of the hand 
and face? 
Dr. Young: I have been on many peer-
review committees charged with look-
ing at this issue. Although the ethics 
can be very troubling, I have resolved 
important questions in my mind by 
examining them through the context 
of human suffering. Our mission as 
Thomas Jefferson wrote, 
'We should never return 
to earlier times when 
all scientific progress 
was prohibited as 
innovation.' The 
thought is still 
modern and relevant. 
Dr. Siegler: This discussion by this 
extraordinary panel has not just been 
about events from 50 years ago; each 
of the panelists spoke of a future that is 
rich in promise and innovation-and 
in ethical issues. It reminds me of an 
extraordinary letter written in 1794 
by Thomas Jefferson to John Adams, 
which says, "We should never return 
to earlier times when all scientific 
progress was prohibited as innova-
tion." The thought is still modem and 
-Dr. Mark Siegler 
physicians and caregivers is to relieve 
suffering, which can take the form of pain, a short-
ened lifespan, or even a debilitating disfigurement of 
the face or a severe limitation, such as after traumatic 
amputation. Looking at the issue this way, I am less 
troubled than I was initially, when I viewed these 
kinds of transplantations as simply altering physical 
appearance or extending ability. 
Dr. Starzl: The next big movement in transplanta-
tion is going to be in composite tissue allotransplan-
tation-that is, transplantation of the face, limbs, etc. 
Mechanisms of alloengraftment have recently been 
uncovered such that it is now possible to formulate 
protocols that use either very light immunosuppres-
sion (avoiding the 20% or 25% rate of renal failure 
at 5 years that we heard about from Dr. Young) or no 
immunosuppression at all.6 Without the heavy burden 
relevant, more than 200 years later. 
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